VOYA Investment Management
GNMX

VOYA Investment Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

VOYA Investment Management’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-12,471
Closed -$23K – 2670
2017
Q1 		$23K Hold
12,471
– – ﹤0.01% 2499
2016
Q4 		$65K Hold
12,471
– – ﹤0.01% 2492
2016
Q3 		$69 Hold
12,471
– – ﹤0.01% 2512
2016
Q2 		$69K Buy
+12,471
New +$65.5K ﹤0.01% 2530
2015
Q3 		– Sell
-14,233
Closed -$87K – 2618
2015
Q2 		$87K Buy
+14,233
New +$110K ﹤0.01% 2638

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

VOYA Investment Management's GNMX Position: Q2 2017 in Review

VOYA Investment Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 12,471 shares — an estimated $23K sold.

VOYA Investment Management first reported a position in GNMX in Q2 2015 and held it in 5 quarters. The position peaked at $87K in Q2 2015. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

  • VOYA Investment Management reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
  • VOYA Investment Management sold 12,471 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $23K.
  • VOYA Investment Management first reported a position in Aevi Genomic Medicine Inc in Q2 2015 and held it in 5 quarters.
  • VOYA Investment Management's Aevi Genomic Medicine Inc position peaked at $87K in Q2 2015.
  • 51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on VOYA Investment Management's 13F filing for Q2 2017, filed 14 Aug 2017.